Read/Post Comments (0) | Recommended this article (0)
Please login to Zacks.com or register to post a comment.
- Latest News
- Most Popular
- Hitting Home Runs & Grand Slams, Not Loud Outs
- RTI: Do Stocks Tank When QE Ends?
- 3 Top-Ranked Consumer ETFs to Buy Now
- This Week's Aggressive Growth Stocks
- Who Wants to Keep "Too Big to Fail" Alive?
- Debt-Ceiling Alarm Bell Tolls
- Avoid These 3 Eurozone ETFs This Summer
- RTI: When Will We Finally See a Pullback?
- Top Stocks with Big Potential Catch-Up Moves
- AWS 5/22: Will Bernanke Show His Hand?
- PFP 5/22: Singular Stock Focus Continues
Recent Quotes
| No Recent Quote currently available |
My Portfolio
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
More Zacks Resources
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
Zacks #1 Stocks on the Move 05/22/2013
| Company Name | Symbol | %Change |
|---|---|---|
| ALLIANCE FIB | AFOP | 9.31% |
| SONIC FOUNDR | SOFO | 7.77% |
| TRI TECH HOL | TRIT | 6.62% |
| A M R CP | AAMRQ | 4.52% |
| FLOWERS FOOD | FLO | 4.31% |
Quick Links
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
Regeneron Pharmaceuticals Inc. ( REGN - Analyst Report ) received some good news when an Independent Data Monitoring Committee (IDMC) recommended the continuation of a late-stage study (VENICE) which is evaluating its cancer therapy Zaltrap (aflibercept) without any modifications.
The study is evaluating the candidate (in conjunction with docetaxel and prednisone) as a first-line therapy in patients suffering from androgen-independent (hormone-refractory) metastatic prostate cancer. The committee arrived at the decision after conducting an interim analysis of the data from the VENICE study. Regeneron is co-developing Zaltrap with Sanofi-Aventis ( SNY - Analyst Report ) .
Final results from the multicenter study, whose primary goal is to increase overall survival following Zaltrap treatment, are expected in 2012. The secondary objective of the study includes measurement of prostate specific antigen and pain coupled with progression-free survival and safety. Progression free survival indicates survival without the worsening of the disease.
If Zaltrap is successfully developed and commercialized, then the top line at Regeneron would be significantly boosted since the market for prostate cancer represents a significantopportunity.
Apart from the VENICE study, Zaltrap is also being evaluated in a phase II study (AFFIRM) as a first-line therapy in patients suffering from metastatic colorectal cancer. The AFFIRM study is evaluating Zaltrap in combination with Folfox (leucovorin, 5-fluorouracil and oxaliplatin). Results from the study are expected in the second half of 2011.
Moreover, Zaltrap was also being evaluated as a combination therapy in a late-stage, multinational study (VELOUR). The study evaluated Zaltrap as a second-line therapy in previously treated patients suffering from metastatic colorectal cancer. Positive results from the study were presented in June 2011.
Our Recommendation
Currently, we have a Neutral stance on Regeneron in the long run. The company carries a Zacks #3 Rank (Hold rating) in the short run.
Read the full Analyst Report on REGN
Read the full Analyst Report on SNY